The Administration for Strategic Preparedness and Response (ASPR) will make 50,000 courses of the small-molecule drug Tpoxx (tecovirimat) from SIGA Technologies (Nasdaq: SIGA) available to help fight the monkeypox outbreak. There have been 13,517 confirmed monkeypox/orthopoxvirus cases in the U.S. to date, according to the CDC. In 2018, Tpoxx became the first drug to win an…
34 of the most innovative pharmaceutical products
The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Tpoxx is effective against human smallpox disease
Tpoxx (tecovirimat) from SIGA Technologies is a unique small-molecule drug. In 2018, it became the first drug to win an FDA indication for smallpox. While smallpox was eradicated around 1980s, governments across the world have worried that the variola virus that causes the disease could provide the basis for bioweapons. The U.S. maintains a stockpile…